Broad Institute of MIT and Harvard

Creating a Fibrolamellar Cancer Dependency Map2020 – 2022 Principal Investigator: Jesse Boehm, PhD, Institute Scientist, Director of the Broad Cancer Model Development Center This resource project is part of the Broad Institute’s Rare Cancer Dependency Map Initiative. It aims to create cell culture research models of FLC and utilize them to determine both a comprehensive …

Read moreBroad Institute of MIT and Harvard

Massachusetts General Hospital

Massachusetts General Hospital (Harvard University) Fibrolamellar Carcinoma Model Development and Analysis2019 – 2021 Principal Investigator: Nabeel Bardeesy, PhD, Associate Professor, Massachusetts General Hospital, Harvard University This is a resource development project for the fibrolamellar cancer research community. The primary goal is to derive a new series of transplantable human FLC tumors grown in immune-deficient mice …

Read moreMassachusetts General Hospital

Cancer Research Institute

FCF has partnered with the prestigious Cancer Research Institute (“CRI”) to specifically focus on the role immunotherapy may have in creating curative therapies for fibrolamellar. CRI has been promoting immunotherapy research for 65 years, long before the establishment cancer treatment and research community recognized immunotherapy as a legitimate prospect for cancer patients. For the past …

Read moreCancer Research Institute

Johns Hopkins, Baltimore, MD

Opening of FLC Peptide Vaccine Clinical Trial2020 A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique …

Read moreJohns Hopkins, Baltimore, MD

Cornell University

Retinoic Acid-Induced Loss of DNAJB1-PRKACA Fusion Protein Expression2019-2020 Principal Investigator: Andrew Yen, PhD, Professor, Department of Biomedical Sciences Co-Principal Investigator: Praveen Sethupathy, PhD, Associate Professor, Department of Biomedical Sciences Fibrolamellar carcinoma (FLC) is driven by the DNAJ-PKAc fusion protein. A potential therapeutic strategy would be to induce loss of this key driver protein of the …

Read moreCornell University

Duke University School of Medicine

Hedgehog and YAP signaling in fibrolamellar carcinoma: Tumor-stroma crosstalk and the cancer stem cell niche2017 – 2019 Principal Investigators: Cynthia Guy, MD, Associate Professor of Pathology; Anna Mae Diehl, MD, Florence McAlister Professor of Medicine, Duke University School of Medicine Fibrolamellar carcinoma has a unique appearance; it is made up of large tumor cells surrounded …

Read moreDuke University School of Medicine

The University of Vermont Cancer Center

Characterizing enzyme inhibition of the DnaJPKAc chimeric protein derived from fibrolamellar hepatocellular carcinomas2017 – 2019 Principal Investigator: Hibba tul Rehman, M.D., University of Vermont Scientists have identified a unique fusion protein, DnaJ-PKAc, which causes this cancer. When overexpressed, this protein causes havoc in the downstream signaling pathways that are involved in cell growth and metabolism …

Read moreThe University of Vermont Cancer Center

University of California San Francisco and Harvard University, Cambridge, MA

Targeting DNAJB1-PRKACA Driven Signaling Dependencies in Fibrolamellar Liver Cancer2019 – 2021 Principal Investigator: John Gordan, MD, PhD, Assistant Professor, Department of Medicine, UCSF Co-Investigator: Nabeel Bardeesy, Associate Professor, Massachusetts General Hospital, Harvard University Even with the identification of a near universal DNAJB1-PRKACA gene fusion (encoding a chimeric protein with a domain of heat shock protein …

Read moreUniversity of California San Francisco and Harvard University, Cambridge, MA

Boston Children’s Hospital

Boston Children’s Hospital (Harvard University) Development of a Human-Derived Liver Progenitor Cell Line with DNAJB1-PRKACA Fusion Gene2019 – 2020 Principal Investigator: Khashayar Vakili, MD, Surgical Director of Liver, Kidney, Intestine, and Multivisceral Transplant Programs, Assistant Professor of Surgery, Harvard Medical School Developing models to study the mechanism by which the DNAJB1-PRKACA fusion protein causes fibrolamellar …

Read moreBoston Children’s Hospital